National Cade Prize for Innovation Names 21 Finalists

Judges for 2023’s National Cade Prize for Innovation named this year’s 21 Fibonacci Finalists. Finalists will compete to win $10,000 in their respective category group—Agriculture and Environmental, Healthcare/Biomedical, IT/Tech, Energy, and Wildcard. One of the five category winners will be selected as the Inventivity™ Grand Prize winner and take home an additional $50,000 prize. Two UF startups -- Lactovid and Analyz -- are listed among the Fibonacci Finalists.

Neobiosis Announces FDA Approval of IND for Use of ViXomeTM in COVID-19 ‘Post COVID Syndrome’

Neobiosis, A UF Accelerate resident client, is a leading research and manufacturing biotechnology company focused on pioneering the development of novel therapeutics from perinatal tissues as a new class of medicines. Today, Neobiosis announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for ViXome™, its drug for the treatment of 'Post COVID Syndrome (AKA "Long Haul COVID Syndrome").

UF researchers discover new way to inhibit virus that causes COVID-19

When the virus that causes COVID-19 enters the body, it hijacks cellular proteins and suppresses the human inflammatory response, allowing the virus to spread. University of Florida researchers have discovered a novel way in the lab to fight rapidly evolving strains of coronaviruses by breaking that cycle.

Targeting a Human Protein To Squash SARS-CoV-2 and Other Viruses

More than two years into the COVID-19 pandemic, people are realizing that the “new normal” will probably involve learning to co-exist with SARS-CoV-2. Some treatments are available, but with new variants emerging, researchers are looking toward new strategies. In ACS Infectious Diseases, scientists now report that apratoxin S4, an anticancer drug candidate that targets a human protein, can interfere with the replication of many viruses, including SARS-CoV-2 and influenza A, offering a possible pan-viral therapy.

Oragenics Announces Publication of Positive Data for Its Nt-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports

UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada (“NRC”) Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.

Oragenics To Participate at the World Vaccine Congress Washington 2022

Oragenics, Inc. (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.

Using AI in the Arts To Promote COVID-19 Vaccines

Sure, it is fun to see an avatar simulate your body movements in real time, but the interactive augmented reality art installation making its way around campus has a serious aim: educating participants about how COVID-19 impacts health and encouraging vaccination.
1 2 3 19